Srs Capital Advisors, Inc. Akebia Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.48 Billion
- Q1 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 24,817 shares of AKBA stock, worth $75,195. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,817
Previous 13,700
81.15%
Holding current value
$75,195
Previous $25,000
88.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AKBA
# of Institutions
157Shares Held
96.8MCall Options Held
98.6KPut Options Held
320K-
Vanguard Group Inc Valley Forge, PA12.7MShares$38.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$35.3 Million0.0% of portfolio
-
State Street Corp Boston, MA6.81MShares$20.6 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$17.4 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA5.03MShares$15.2 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $557M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...